Drug Profile
Research programme: cancer therapeutics - Revitope Oncology
Latest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator Revitope
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Haematological-malignancies in USA (Parenteral)
- 28 Mar 2020 No recent reports of development identified for research development in Solid-tumours in USA (Parenteral)
- 08 Feb 2016 Early research in Haematological malignancies in USA (Parenteral)